Loading…
Upstream Bio, Inc. is projected to rise to $6.99 by 2027, a +11% move from its current price of $6.31. UPB is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/2/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 3 | $6.15 | $6.31 | $6.47 | -0.01% |
| Aug 4 | $6.09 | $6.31 | $6.54 | -0.01% |
| Aug 5 | $6.04 | $6.31 | $6.59 | -0.02% |
| Aug 6 | $6.00 | $6.31 | $6.63 | -0.02% |
| Aug 7 | $5.96 | $6.31 | $6.67 | -0.03% |
| Aug 8 | $5.93 | $6.31 | $6.71 | -0.03% |
| Aug 9 | $5.90 | $6.31 | $6.74 | -0.04% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $5.90 | $6.31 | $6.74 | -0.04% |
| Week 2 | $5.74 | $6.30 | $6.92 | -0.08% |
| Week 3 | $5.62 | $6.30 | $7.07 | -0.12% |
| Week 4 | $5.52 | $6.30 | $7.19 | -0.16% |
| Week 5 | $5.43 | $6.30 | $7.30 | -0.20% |
| Week 6 | $5.35 | $6.29 | $7.40 | -0.24% |
| Week 7 | $5.28 | $6.29 | $7.50 | -0.28% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Upstream Bio, Inc. (UPB) is a clinical-stage biotechnology company in the Healthcare sector that develops treatments for inflammatory diseases with a focus on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease, and in Phase I for treating chronic obstructive pulmonary disease.
The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.
As a biotechnology company, Upstream Bio operates in the healthcare space and is identified by its UPB ticker in the market. Its focus on inflammatory and respiratory conditions positions it within the biotechnology and pharmaceutical field as it advances its clinical programs toward potential approvals and patient impact.
The description reflects a company profile anchored in clinical development and location, presenting a small-cap biotech with ongoing trials and a recent corporate formation in 2021, based in Waltham, MA.
The stock is trading at $6.40, reflecting its current price.
It has a market cap of $348.29M and ranks 3291. In the near term, the forecast shows a largely flat to modest move, with 2026: avg $6.40, min $5.92, max $7.84, ROI 0, sentiment NEUTRAL.
These figures provide a snapshot of the stock’s size, current value, and concise near-term outlook based on the available projections.
A major floor 18.9% below — a decisive break under it would weaken the trend.
Price is testing support right now (1.0% away) — a key level to hold.
The nearest ceiling, 26.5% above — a clean break opens room to run.
A major ceiling 66.2% above — clearing it would confirm fresh momentum.
Key UPB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of UPB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $6.42 | Sell | $6.44 | Sell |
| MA 10 | $6.55 | Sell | $6.57 | Sell |
| MA 20 | $7.00 | Sell | $6.76 | Sell |
| MA 50 | $7.06 | Sell | $7.38 | Sell |
| MA 100 | $8.18 | Sell | $9.34 | Sell |
| MA 200 | $15.96 | Sell | $12.26 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 35.67 | Neutral |
| Stoch RSI (14) | 4.15 | Buy |
| CCI (20) | -101.25 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.06 | Sell |
| ROC (12) | -13.20 | Sell |
| Bollinger %B (20,2) | 0.18 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.29 | Sell |
| Awesome (5,34) | -0.38 | Sell |
| Ultimate (7,14,28) | 28.80 | Buy |
| Momentum (10) | -0.70 | Sell |
| Aroon Osc (25) | -68.00 | Sell |
| Hull MA (9) | 6.40 | Sell |
| ADX (14) | 21.09 | Sell |
| ATR (14) | 0.15 | Info |
Sentiment in the near term is BEARISH.
The RSI(14) is 40, with the SMA50 at $7.34 and the SMA200 at $16.35, indicating mixed momentum and a lack of strong upside pressure relative to the shorter-term trend.
Support is at $5.92 and resistance at $7.98, with a 30-day price range from $5.33 to $7.69, illustrating limited movement within a tight window.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $5.92 | $6.31 | $7.64 | 0% | Neutral | |
| $5.62 | $6.99 | $9.17 | +11% | Neutral | |
| $5.55 | $7.09 | $9.63 | +12% | Neutral | |
| $5.24 | $6.83 | $9.53 | +8% | Neutral | |
| $5.71 | $7.59 | $10.83 | +20% | Bullish | |
| $5.99 | $8.10 | $11.80 | +28% | Bullish | |
| $6.91 | $9.48 | $14.06 | +50% | Bullish | |
| $7.74 | $10.78 | $16.25 | +71% | Bullish | |
| $7.47 | $10.55 | $16.15 | +67% | Bullish | |
| $7.84 | $11.22 | $17.41 | +78% | Bullish | |
| $10.84 | $16.48 | $27.09 | +161% | Bullish | |
| $15.04 | $25.31 | $45.32 | +301% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $5.92 | $6.31 | $7.37 | +0.00% |
| September 2026 | $5.26 | $6.21 | $7.52 | -1.66% |
| October 2026 | $5.29 | $6.28 | $7.68 | +1.15% |
| November 2026 | $5.16 | $6.15 | $7.59 | -1.96% |
| December 2026 | $5.13 | $6.15 | $7.64 | -0.10% |
Click any year to see its month-by-month UPB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect UPB to range from $5.92 to $7.64 through 2026. The $6.31 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The UPB price prediction for 2027 points to an average of $6.99 (low $5.62, high $9.17) — a potential gain of +11% on today's $6.31. A consolidation phase looks the most probable path here.
In 2028, UPB is projected to trade between $5.55 and $9.63, averaging $7.09 — a potential gain of +12% from today's $6.31. That is up +1% on the projected 2027 average. Price action looks broadly range-bound.
Upstream Bio, Inc.'s 2029 outlook centres on $6.83, within a $5.24 to $9.53 range. That is -4% versus the projected 2028 average. That marks a +8% change versus current levels. A consolidation phase looks the most probable path here.
By 2030, UPB could reach as high as $10.83, with a base case around $7.59 and support toward $5.71 — roughly +20% from $6.31. Momentum favours further upside here.
Expect UPB to range from $5.99 to $11.80 through 2031. The $8.10 average target implies a +28% move from current prices. That is up +7% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The UPB price prediction for 2032 points to an average of $9.48 (low $6.91, high $14.06) — a potential gain of +50% on today's $6.31. Momentum favours further upside here.
In 2033, UPB is projected to trade between $7.74 and $16.25, averaging $10.78 — a potential gain of +71% from today's $6.31. That is up +14% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Upstream Bio, Inc.'s 2034 outlook centres on $10.55, within a $7.47 to $16.15 range. That is -2% versus the projected 2033 average. That marks a +67% change versus current levels. Momentum favours further upside here.
By 2035, UPB could reach as high as $17.41, with a base case around $11.22 and support toward $7.84 — roughly +78% from $6.31. Buyers look set to stay in control over this stretch.
Expect UPB to range from $10.84 to $27.09 through 2040. The $16.48 average target implies a +161% move from current prices. That is up +47% on the projected 2035 average. Momentum favours further upside here.
The UPB price prediction for 2050 points to an average of $25.31 (low $15.04, high $45.32) — a potential gain of +301% on today's $6.31. Buyers look set to stay in control over this stretch.
Investing $1,000 in UPB today (≈ 158.478605 UPB) could be worth
$4,011.37
+$3,011.37 (+301%) by 2050 · US Dollar
Based on the average projected UPB price of $25.31 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in UPBwould be worth at today's price.
$1,000 invested in UPB on Jul 31, 2025 (≈ 65.316785 UPB) would be worth
$412.15
-$587.85 (-58.8%) today · 0.41× · US Dollar
Based on a UPB entry price of $15.31 vs. today's $6.31.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $6.41 | $984.4 | -1.6% |
| 1 month ago | $7.28 | $866.76 | -13.3% |
| 3 months ago | $9.4 | $671.28 | -32.9% |
| 6 months ago | $29.94 | $210.75 | -78.9% |
| 1 year ago | $15.31 | $412.15 | -58.8% |
| All time (1.8y) ago | $22 | $286.82 | -71.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our UPB forecast.
Our base-case forecast reaches $13.00 around 2040.
Implied market cap at $13.00: $707.46M
The multi-year forecast shows upside potential beginning in 2030 and intensifying through 2050. The 2030 estimate places the average price at $7.43 with a min of $5.49 and a max of $10.84, and an ROI of 16, with a NEUTRAL tone.
From 2031 to 2035, the outlook turns more bullish as averages rise: 2031 avg $7.80, ROI 21.9; 2032 avg $9.26, ROI 44.6; 2033 avg $10.56, ROI 65; 2034 avg $10.15, ROI 58.6; 2035 avg $10.91, ROI 70.5, all with bullish sentiment.
Longer horizons show substantial gains: 2040 avg $15.63, ROI 144.2; 2050 avg $23.90, ROI 273.5, with ongoing bullish sentiment. These are estimates, not guarantees, and depend on many factors including clinical progress, regulatory outcomes, and market conditions.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $7.43, with a min of $5.49 and a max of $10.84, and an ROI of 16. Sentiment is NEUTRAL.
Forecasts indicate neutral near term with a path to bullish momentum starting in 2031, as the averages rise to $7.80 in 2031, then to $9.26 in 2032 and beyond, with ROIs up to 273.5 by 2050 and a bullish sentiment through 2050.
Yes. The 2030 max forecast is $10.84, and later years show higher highs (e.g., 2032 max $14.08, 2033 max $16.34, 2035 max $17.42, 2040 max $26.57, 2050 max $44.52).
Current price is $6.40 and market cap is $348.29M.
The 30-day picture is Bearish, with RSI 14 at 40, SMA50 at $7.34, SMA200 at $16.35, support at $5.92, resistance at $7.98, and a 30-day range of $5.33 to $7.69.
Upstream Bio, Inc. Community Discussion
0Share your Upstream Bio, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.